908 Devices (MASS) Stock Price, News & Analysis

Company Overview

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $3.37 to $3.49
• 50-Day Range: $3.39 to $5.79
• 52-Week Range: $3.36 to $12.51
• Volume: 126,090 shs
• Average Volume: 201,882 shs
• Market Capitalization: $120.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

908 Devices Stock Analysis - MarketRank™

908 Devices scored higher than 61% of companies evaluated by MarketBeat, and ranked 525th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

908 Devices has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

908 Devices has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 908 Devices are expected to grow in the coming year, from ($1.21) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 908 Devices is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 908 Devices is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

908 Devices has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.18% of the float of 908 Devices has been sold short.

Short Interest Ratio / Days to Cover

908 Devices has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in 908 Devices has recently increased by 0.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

908 Devices does not currently pay a dividend.

Dividend Growth

908 Devices does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.18% of the float of 908 Devices has been sold short.

Short Interest Ratio / Days to Cover

908 Devices has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in 908 Devices has recently increased by 0.76%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

908 Devices has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for 908 Devices this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for MASS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 908 Devices insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.80% of the stock of 908 Devices is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.06% of the stock of 908 Devices is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MASS Stock Analysis - Frequently Asked Questions

How have MASS shares performed this year?

908 Devices' stock was trading at $11.22 at the beginning of 2024. Since then, MASS stock has decreased by 69.0% and is now trading at $3.48.
View the best growth stocks for 2024 here.

How were 908 Devices' earnings last quarter?

908 Devices Inc. (NASDAQ:MASS) posted its earnings results on Tuesday, August, 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.02. The firm had revenue of $14.05 million for the quarter, compared to analyst estimates of $13.69 million. 908 Devices had a negative net margin of 72.10% and a negative trailing twelve-month return on equity of 22.47%.

When did 908 Devices IPO?

908 Devices (MASS) raised $101 million in an IPO on Friday, December 18th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. Cowen, SVB Leerink, Stifel and William Blair served as the underwriters for the IPO.

Who are 908 Devices' major shareholders?

908 Devices' top institutional shareholders include SG Americas Securities LLC (0.03%). Insiders that own company stock include Christopher D Brown, Kevin J Knopp, Joseph H Iv Griffith, Trent A Basarsky, Mark Spoto, Michael S Turner and John Kenneweg.
View institutional ownership trends.

How do I buy shares of 908 Devices?

Shares of MASS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/06/2024
• Today: 10/04/2024
• Next Earnings (Estimated): 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Measuring & controlling devices, not elsewhere classified
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:MASS
• CUSIP: N/A
• CIK: 1555279
• Web: www.908devices.com
• Phone: 857-254-1500
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +302.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,400,000.00
• Net Margins: -72.10%
• Pretax Margin: -72.63%
• Return on Equity: -22.47%
• Return on Assets: -18.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.09
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $52.69 million
• Price / Sales: 2.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.11 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 34,485,000
• Free Float: 24,898,000
• Market Cap: $120.01 million
• Optionable: Optionable
• Beta: 0.97